MedTrace Logo

TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN

NCT00539630 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2007-10-04

No results posted yet for this study

Summary

To describe the clinical response rate in two groups (Docetaxel plus cisplatin plus 5-FU, versus Cisplatin plus 5-FU) after 3 cycle of neoadjuvant chemotherapy.

Conditions

  • Carcinoma, Squamous Cell

Interventions

DRUG

Docetaxel

Sponsors & Collaborators

Principal Investigators

  • Hyang Rim Kim · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539630 on ClinicalTrials.gov